Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6538.

https://doi.org/10.1182/blood-2023-180060

Published: 2023

Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4142–4143.

https://doi.org/10.1182/blood-2022-170596

Published: 2022